DHAD in Adults with Metastatic Malignant Melanoma

Closed

Phase

Published

Abbreviated Title

Activated

07/02/1980

Closed

10/18/1983

Publication Information Expand/Collapse

1985

Phase II trial of 1,4-dihydorxy-5, 8-bis((2-((2-hydroxyethyl) amino) ethyl) amino 9,10-anthracenedione dihydrochloride) (NSC 301739, DHAD) in patients with metastatic malignant melanoma.

SA Taylor;BT Tranum;DD Von Hoff;JJ Costanzi Invest New Drugs 3:67-69

1983

Phase II trial of Dihydroxyanthracenedione in advanced malignant melanoma: A Southwest Oncology Group study.

S Taylor;D Von Hoff;F Panettiere ASCO, #C-881

Southwest Oncology Group Phase II studies with Mitoxantrone in nonhematologic malignancies.

RL Stephens;DD Von Hoff;SA Taylor;WA Knight III;RB Livingston;FE Bull;J Cowan;RD Hilgers;CK Osborne;GA Gates;G Clark In: New Anticancer Drugs: Mitoxantrone and Bisantrene . M Rozencweig, et al, eds. New York: Raven Press, 125-30

Cardiotoxicity in patients treated with Mitoxantrone on Southwest Oncology Group Phase II protocols.

GM Clark;LK Tokaz;DD Von Hoff;LL Thoi;CA Coltman Jr Cancer Treat Symp 3:25-30

1981

Southwest Oncology Group (SWOG) Phase II with mitoxantrone in non-hematologic malignancies.

RL Stephens;G Clark 3rd NCI-EORTC Symposium on New Drugs in Cancer Therapy (October 15-17, 1981), #36